Mebendazole Shows Anticancer Activity in Ovarian Cancer Spheroids (2026 Study)

Ovarian cancer remains the leading cause of gynecological cancer mortality worldwide, with most patients eventually developing resistance to first-line platinum-based chemotherapy. Drug repurposing—the strategy of finding new therapeutic uses for existing medications—has gained significant attention as a way to bypass the lengthy and expensive traditional drug development pipeline. Among repurposed candidates, mebendazole, a well-established benzimidazole anthelmintic, has emerged as a promising option due to its preclinical anticancer activity across multiple tumor types. Patients exploring metabolic and repurposed-drug protocols often pair such research with tools like the dosing calculator to structure their approach safely.

The new study, published in the Journal of Biophotonics in 2026, introduces an innovative imaging approach to evaluate mebendazole's efficacy against ovarian cancer. Researchers used spectral-domain optical coherence tomography (SD-OCT)—a non-invasive, high-resolution imaging technique—to monitor multicellular tumor spheroids derived from both wild-type and cisplatin-resistant OVCAR8 cell lines. This method allowed real-time, longitudinal assessment of structural changes during an 11-day treatment period, offering a more dynamic view of drug response than conventional endpoint assays alone.

Mebendazole's potential in oncology has been discussed in several in-depth reviews on Sanare Lab. For readers interested in how benzimidazoles compare in cancer research, our fenbendazole vs. mebendazole comparison covers the structural and mechanistic differences between these two anthelmintics. The Marik protocol also provides context on how mebendazole is positioned within broader metabolic therapy strategies.

Table of Contents

• Study Design and Methods
• What the Researchers Found
• How Mebendazole Works in Ovarian Cancer
• Clinical Implications
• Frequently Asked Questions

Study Design and Methods

The study employed a preclinical spheroid model using the OVCAR8 human ovarian cancer cell line. Two variants were tested: wild-type (WT) cells and a cisplatin-resistant (CPR) subline, which mimics the clinical scenario of acquired drug resistance that limits long-term survival in ovarian cancer patients.

Researchers cultured these cells as three-dimensional multicellular tumor spheroids—compact cellular aggregates that better replicate the tumor microenvironment than traditional two-dimensional monolayer cultures. Over an 11-day period, spheroids were treated with mebendazole while being monitored using spectral-domain optical coherence tomography (SD-OCT).

SD-OCT is a non-invasive optical imaging modality that captures cross-sectional images of biological tissues with micrometer-scale resolution. In this study, it enabled longitudinal tracking of spheroid volume and internal texture changes without disrupting the cultures. Four complementary analyses were performed: volumetric measurement, texture analysis from OCT images, and standard viability assays to cross-validate the imaging findings.

What the Researchers Found

Mebendazole treatment produced measurable reductions in spheroid volume in both wild-type and cisplatin-resistant OVCAR8 models over the 11-day observation period. The SD-OCT imaging revealed progressive structural changes in treated spheroids, including alterations in internal texture patterns consistent with cellular disruption and reduced viability.

The cisplatin-resistant line responded to mebendazole, suggesting that the drug's mechanism of action differs from platinum-based chemotherapy. This is significant because acquired resistance to cisplatin is a major barrier in ovarian cancer treatment, and agents with non-overlapping mechanisms are urgently needed.

Texture analysis from the OCT images provided additional confirmation of drug-induced changes, demonstrating that SD-OCT can serve as a sensitive, label-free tool for monitoring anticancer drug responses in three-dimensional tumor models. The study did not report quantitative efficacy metrics such as half-maximal inhibitory concentration (IC50) values or survival curves, and no animal or human data were included.

How Mebendazole Works in Ovarian Cancer

Mebendazole is a microtubule-disrupting agent that binds to β-tubulin, interfering with the polymerization of microtubules required for cell division. In cancer cells, this disruption not only blocks mitosis but also triggers downstream stress responses that can lead to apoptosis (programmed cell death).

Beyond microtubule inhibition, mebendazole has been shown in other studies to affect multiple cancer-relevant pathways, including glucose metabolism, angiogenesis, and the epithelial-mesenchymal transition (EMT). In the context of ovarian cancer, these pleiotropic effects may help explain why mebendazole retained activity against the cisplatin-resistant OVCAR8 line—its targets extend beyond the DNA-damage response mechanisms that platinum drugs exploit.

However, the specific molecular targets in ovarian cancer spheroids were not fully characterized in this study. The OCT-based approach focused on structural and phenotypic outcomes rather than mechanistic pathway analysis.

Clinical Implications

While these findings are preclinical, they contribute to a growing body of evidence supporting mebendazole as a candidate for ovarian cancer drug repurposing. The use of OCT imaging is particularly noteworthy because it offers a non-destructive, real-time monitoring approach that could be adapted for other preclinical drug screening workflows.

The response of cisplatin-resistant spheroids is especially relevant clinically, as resistance to platinum-based therapy is a leading cause of treatment failure in ovarian cancer. If mebendazole's activity in resistant models translates to human tumors, it could eventually complement existing treatment regimens or serve as a maintenance therapy option.

It is important to emphasize that no clinical trials have yet demonstrated mebendazole's efficacy in ovarian cancer patients. All current evidence is derived from cell culture and animal models. Patients should not self-administer mebendazole for cancer outside of approved clinical trials or physician supervision.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested benzimidazole products referenced in the research above. Links are provided for convenience — always review the label and consult a professional before use.

Disclaimer: Links are informational and for convenience. This site does not provide medical advice and does not endorse any specific vendor. Always verify product quality, labeling, and consult a licensed professional for health decisions.

References

1. Majd SM, et al. Evaluating the Efficacy of Mebendazole Repurposing for Ovarian Cancer Therapy Using Optical Coherence Tomography. J Biophotonics. 2026. PMID: 40922675.

Medical Disclaimer

This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. The research described is preclinical (laboratory and animal studies) and has not been validated in human clinical trials. Always consult a qualified healthcare provider before making any decisions about cancer treatment, drug use, or dietary changes. Sanare Lab does not provide personalized medical advice and does not endorse self-treatment with investigational agents.